Processing

Please wait...

Settings

Settings

Goto Application

1. EP2305238 - N-acetyl-L-cysteine for the treatment of endometriosis

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. A pharmaceutical composition comprising N-acetyl-L-cysteine for use in the treatment of a human or mammal having endometriosis characterized in that the composition is for oral administration
for a time period of two months or more;
for 3-5 consecutive days each week, with 2-4 days of interruption; and
at an N-acetyl-L-cysteine dose that is between 20 and 90 mg/kg/day, on administration days.
  2. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to the previous claim, characterized in administration at an N-acetyl-L-cysteine dose of between 30 and 60 mg/kg/day, on administration days.
  3. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to the previous claim, characterized in administration at an N-acetyl-L-cysteine dose of between 30 and 45 mg/kg/day, on administration days.
  4. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of the previous claims, characterized in that it is protected from light.
  5. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of the previous claims, characterized in that it is a water soluble tablet.
  6. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of the previous claims, characterized in that it contains sodium hydrogen carbonate.
  7. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of the previous claims in treating pain caused by endometriosis.
  8. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of claims 1-6 in promoting pregnancy.
  9. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of claims 1-6 in pre-treating mammals having endometriosis before laparoscopy or surgery.
  10. A pharmaceutical composition comprising N-acetyl-L-cysteine for use according to any of claims 1-6 in treatment after laparoscopy or surgery, to prevent recurrences of endometriotic lesions.